KRAS and CREBBP mutations: A relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia

Leukemia

Volumn 29, Issue 8, 2015, Pages 1656-1667

  Malinowska Ozdowy, K ^a   Frech, C ^a   Schonegger A ^b   Eckert, C ^c   Cazzaniga, G ^d   Stanulla, M ^e   Zur Stadt, U ^f   Mecklenbrauker A ^a   Schuster, M ^b   Kneidinger, D ^a   Von Stackelberg, A ^c   Locatelli, F ^g   Schrappe, M ^h   Horstmann, M A ^f   Attarbaschi, A ⁱ   Bock, C ^b   Mann, G ⁱ   Haas, O A ^a,i   Panzer Grumayer R ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SAN GERARDO HOSPITAL   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FLT3 LIGAND; K RAS PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; ANTINEOPLASTIC AGENT; CREBBP PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CHILDHOOD LEUKEMIA; CHROMATIN; COHORT ANALYSIS; GENE SEQUENCE; GENE TARGETING; HIGH RISK POPULATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HYPERDIPLOID ACUTE LYMPHOBLASTIC LEUKEMIA; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; MUTATION RATE; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; ADOLESCENT; CANCER STAGING; CASE CONTROL STUDY; CHILD; CLONAL EVOLUTION; COMPARATIVE STUDY; DIPLOIDY; FEMALE; FOLLOW UP; GENETICS; MALE; MORTALITY; MUTATION; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; CLONAL EVOLUTION; CREB-BINDING PROTEIN; DIPLOIDY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE;

EID: 84938983358     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.107     Document Type: Article

References (48)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
3. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
4. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28: 2339-2347.
5. Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2009; 48: 637-660.
6. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639-649.
7. Panzer-Grumayer ER, Fasching K, Panzer S, Hettinger K, Schmitt K, Stockler-Ipsiroglu S et al. Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis. Blood 2002; 100: 347-349.
8. Maia AT, van der Velden VH, Harrison CJ, Szczepanski T, Williams MD, Griffiths MJ et al. Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia 2003; 17: 2202-2206.
9. Paulsson K, Forestier E, Lilljebjorn H, Heldrup J, Behrendtz M, Young BD et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 21719-21724.
10. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
11. Kawamata N, Ogawa S, Zimmermann M, Kato M, Sanada M, Hemminki K et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008; 111: 776-784.
12. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
13. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
14. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322: 1377-1380.
15. Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 2011; 117: 2658-2667.
16. Davidsson J, Paulsson K, Lindgren D, Lilljebjorn H, Chaplin T, Forestier E et al. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia 2010; 24: 924-931.
17. Inthal A, Zeitlhofer P, Zeginigg M, Morak M, Grausenburger R, Fronkova E et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012; 26: 1797-1803.
18. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376: 348-351.
19. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
20. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
21. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 3080-3087.
22. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grumayer R et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 2013; 31: 2736-2742.
23. Escherich G, Zimmermann M, Janka-Schaub G. Co ALLsg. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer 2013; 60: 254-257.
24. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
26. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
27. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
28. Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM et al. Using Dro-sophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. Front Genet 2012; 3: 35.
29. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
30. Wendl MC, Wallis JW, Lin L, Kandoth C, Mardis ER, Wilson RK et al. PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioin-formatics 2011; 27: 1595-1602.
31. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012; 22: 1589-1598.
32. Kaplan EL MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 4.
33. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
34. Paulsson K, Horvat A, Strombeck B, Nilsson F, Heldrup J, Behrendtz M et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2008; 47: 26-33.
35. Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia 2005; 19: 415-419.
36. Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One 2013; 8: e83244.
37. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
38. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia-long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer 2013; 49: 1346-1355.
39. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
40. Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S et al. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 2012; 120: 5134-5142.
41. Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y et al. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet 2012; 8: e1002533.
42. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-252.
43. Bedford DC, Brindle PK. Is histone acetylation the most important physiological function for CBP and p300? Aging 2012; 4: 247-255.
44. Butler JS, Koutelou E, Schibler AC, Dent SY. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics 2012; 4: 163-177.
45. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hemato-logic malignancies. Blood 2012; 120: 3397-3406.
46. Omerovic J, Laude AJ, Prior IA. Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci 2007; 64: 2575-2589.
47. Nelson ML, Kang HS, Lee GM, Blaszczak AG, Lau DK, McIntosh LP et al. Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc Natl Acad Sci USA 2010; 107: 10026-10031.
48. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C et al. Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-drivers and confer sensitivity to MEK inhibition. Blood 2014; 124: 3420-3430.